24 completed. 24 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 24 | Completed 24 |
Follow Dermatomycoses: new trials by email Literature Review of Dermatomycoses trials Research Report on Dermatomycoses
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Fluconazole vs Oral Terbinafine for Tinea Capitis in Children Aged 2-10 Years Fluconazole., Terbinafine., Ketoconazole 2% shampoo - Tinea Capitis | Phase 4 | Completed | Dr. Amara Safdar | 64 | 2025-12-01 | 2026-11-10 |
| 8% Sulphur-Aloe Vera Soap as an Adjuvant Treatment for Pityriasis Versicolor 8% sulphur and A. vera soap - Pityriasis Versicolor | Phase 4 | Completed | Universitas Padjadjaran | 42 | 2023-08-25 | 2024-03-26 |
| Topical Amphotericin B in 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis amphotericin B in 30% DMSO, 30% DMSO - Fungal Infection, Onychomycosis | Phase 4 | Completed | Mahidol University | 19 | 2019-01-15 | 2021-09-28 |
| The Comparative Assessment of Mycological Efficacy, Safety, Recurrence, and Cost-effectiveness of Selenium Sulfide 1.8% Shampoo Versus Ketoconazole 2% Shampoo in Pityriasis Versicolor: a Double-blind Randomized Controlled Trial shampoo with different composition - Pityriasis Versicolor | Phase 4 | Completed | Universitas Indonesia | 100 | 2018-09-01 | 2019-07-05 |
| Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis Jublia® - Mild to Moderate Onychomycosis Due to Dermatophyte | Phase 4 | Completed | Dong-A ST Co., Ltd. | 97 | 2017-11-10 | 2021-04-27 |
| Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis Efinaconazole - Onychomycosis | Phase 4 | Completed | Bausch Health Americas, Inc. | 62 | 2016-08-04 | 2021-11-01 |
| Comparison Between Long-pulsed Nd:YAG, Amorolfine and Combination Treatment in Treating Non-dermatophyte Onychomycosis 1,064nm Long-pulsed Nd:YAG, Amorolfine - Non-dermatophyte Onychomycosis | Phase 4 | Completed | Mahidol University | 60 | 2016-08-01 | 2021-09-28 |
| Safety and Efficacy of Product 33525 (Luliconazole Cream 1%) in Pediatric Participants With Tinea Corporis Luliconazole Cream 1%, Vehicle Cream - Tinea Corporis | Phase 4 | Completed | Bausch Health Americas, Inc. | 75 | 2016-02-08 | 2019-11-27 |
| Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1% Loceryl Nail Lacquer, Urea Ointment, Bifonazole Cream - Foot Dermatoses | Phase 4 | Completed | Galderma R&D | 22 | 2016-01-01 | 2021-02-17 |
| Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to Severe Tinea Pedis or Tinea Cruris Luliconazole Cream 1% - Tinea Pedis, Tinea Cruris | Phase 4 | Completed | Bausch Health Americas, Inc. | 30 | 2015-12-02 | 2019-11-27 |
| An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents Tavaborole 5% Topical Solution - Onychomycosis, Tinea Unguium | Phase 4 | Completed | Pfizer | 55 | 2015-10-22 | 2018-04-17 |
| Study Evaluating the Effect of Jublia on Dermatophytomas Jublia (Efinaconazole 10% Topical Solution) - Onychomycosis, Dermatophytosis | Phase 4 | Completed | University of Alabama at Birmingham | 19 | 2015-09-01 | 2019-12-10 |
| Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer Loceryl NL, Ciclopirox NL - Foot Dermatoses | Phase 4 | Completed | Galderma R&D | 20 | 2015-09-01 | 2021-03-22 |
| A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment Nailprotex - Onychomycosis, Chronic Paronychia | Phase 4 | Completed | Mahidol University | 19 | 2015-07-01 | 2016-06-17 |
| Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris Omeprazole 40 mg, Luliconazole Cream 1% - Tinea Pedis, Tinea Cruris | Phase 4 | Completed | Bausch & Lomb Incorporated | 20 | 2015-02-03 | 2019-11-27 |
| Pediatric Subjects With Tinea Corporis Naftin Cream, Placebo Cream - Tinea Corporis | Phase 4 | Completed | Merz North America, Inc. | 230 | 2014-08-01 | 2016-10-28 |
| Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish Loceryl NL + Cosmetic varnish, Loceryl NL 12 weeks, Loceryl NL 15 months - Foot Dermatoses | Phase 4 | Completed | Galderma R&D | 50 | 2014-02-01 | 2023-01-19 |
| An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis Naftin® Cream, 2% (younger pediatric cohort), Naftin® Cream, 2% (older pediatric cohort) - Tinea Corporis | Phase 4 | Completed | Merz North America, Inc. | 27 | 2014-01-01 | 2016-10-28 |
| Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis Resin Lacquer, Amorolfine, Terbinafine - Onychomycosis | Phase 4 | Completed | Helsinki University Central Hospital | 129 | 2013-10-01 | 2015-11-30 |
| Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis NAFT500 (pediatric), NAFT600 (pediatric), NAFT500 (adult) - Tinea Pedis, Tinea Cruris | Phase 4 | Completed | Merz North America, Inc. | 56 | 2012-10-01 | 2016-07-14 |
Showing 20 of 24. Sign in to see all of them.
Onychomycosis (13) · Tinea (5) · Foot Dermatoses (3) · Tinea Cruris (3) · Tinea Pedis (3) · Tinea Versicolor (3) · Mycoses (2) · Aspergillosis (1) · Mycetoma (1) · Tinea Capitis (1)
Bacterial Infections and Mycoses (24) · Infections (24) · Skin Diseases (24) · Skin Diseases, Infectious (24) · Skin and Connective Tissue Diseases (24) · Mycoses (22) · Tinea (15) · Nail Diseases (13) · Foot Diseases (6) · Dermatitis (3) · Foot Dermatoses (3) · Intertrigo (3) · Pathological Conditions, Signs and Symptoms (3) · Pruritus (3)
efinaconazole (3) · Itraconazole (2) · Ketoconazole (2) · Solutions (2) · Terbinafine (2) · amorolfine (2) · Amphotericin B (1) · Ciclopirox (1) · Dimethyl Sulfoxide (1) · Fluconazole (1) · Omeprazole (1) · Sulfur (1) · Therapeutics (1) · Urea (1) · bifonazole (1)
Bausch Health Americas, Inc. (3) · Galderma R&D (3) · Mahidol University (3) · Merz North America, Inc. (3) · Bausch & Lomb Incorporated (1) · Boni Elewski, MD (1) · Dong-A ST Co., Ltd. (1) · Dr. Amara Safdar (1) · Helsinki University Central Hospital (1) · Janssen Korea, Ltd., Korea (1) · Pfizer (1) · Post Graduate Institute of Medical Education and Research, Chandigarh (1) · Rady Children's Hospital, San Diego (1) · Universitas Indonesia (1) · Universitas Padjadjaran (1)
United States (9) · Dominican Republic (6) · Honduras (5) · Thailand (3) · Iceland (2) · Indonesia (2) · Finland (1) · Germany (1) · India (1) · Pakistan (1) · Panama (1) · Puerto Rico (1) · South Korea (1)
Anya Loncaric (3) · Alan Fleischer, MD (2) · Boni E Elewski, MD (2) · Alan B. Fleischer, MD (1) · Binu Alexander, MD (1) · Charussri Leeyaphan, MD (1) · Janne J. Jokinen, MD, PhD (1) · Risa Miliawati Nurul Hidayah, MD, Ph.D (1) · Sheila F Friedlander, MD (1) · Sumanas Bunyaratavej, MD (1)
PMID 10233295, PMID 10642676, PMID 14723731, PMID 20347657, PMID 21820203, PMID 22236569, PMID 22976905, PMID 23278851, PMID 23416171, PMID 23496375, PMID 24079583, PMID 25013957, PMID 25639524, PMID 26471716, PMID 27799043, PMID 27815659, PMID 30811142
2015 (1)